https://twitter.com/anvisa_oficial/status/1400984068758585348
–
Immediately, the Twitter account of the vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology celebrated the announcement with a string of messages and mainly remarked that “Brazil became the 67th country in the world to authorize Sputnik V.” .
The determination came after a meeting attended by Russian representatives who answered questions about the development.
After hearing the responses, the majority of the Anvisa members voted positively: the five directors were in favor but there were three technical opinions that expressed their need to “take some notes,” local media said.
The director of the agency, Alex Machado Camposstated: “The exceptional and temporary importation of the following quantity is authorized, corresponding to doses for immunization of 1% of the national population, within the schedule sent by the Ministry of Health: 4 million doses.”
The president of Anvisa, Antônio Barra Torres, reported that the entity “never had any attachment to bureaucratic issues” and that, “without the inspection that evaluates good manufacturing practices for vaccine supplies, it is not possible to certify the actual manufacturing conditions of the vaccine. product”.
Meanwhile, Kirill Dmitriev, executive director of the Russian Direct Investment Fund, said that the approval “will open access to one of the best drugs against the coronavirus in the world.”
“All the necessary documents were submitted from the outset to ANVISA, and subsequently none of the questions posed by the regulator remained unanswered after the decision to postpone the approval of” Sputnik V “,” he stressed.
–
